Last reviewed: July 8, 2026
Last updated: July 8, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, the active ingredient in Wegovy, produced an average weight loss of 15 percent of starting body weight in clinical trials—a meaningful outcome for adults managing obesity. However, actual weight loss varies significantly between individuals based on genetics, adherence, diet, and exercise patterns. Understanding realistic expectations and personalized factors can help you make informed decisions about whether semaglutide therapy aligns with your health goals.
Clinical Trial Results for Semaglutide Weight Loss
The landmark STEP trials demonstrated that patients taking semaglutide lost between 15 and 22 percent of their starting body weight over 68 weeks, compared to 2–3 percent weight loss in placebo groups. In the STEP 3 trial specifically, participants averaged 16 percent weight loss, with about 80 percent of patients achieving at least 5 percent weight reduction. These trials included patients with obesity and overweight conditions, many with weight-related health concerns such as type 2 diabetes or cardiovascular risk factors.
Weight loss typically occurs progressively over the first 12–16 weeks as your body adjusts to semaglutide's appetite-regulating effects. Most patients reach maximum weight loss between weeks 52 and 68 of consistent therapy. The medication works by activating GLP-1 receptors in your brain, which signal fullness and reduce hunger drive, allowing you to eat less without intense cravings or deprivation-style restriction.
Why Individual Weight Loss Outcomes Vary Significantly
Your genetics play a critical role in how your body responds to semaglutide therapy. Variations in genes like GLP1R, GIPR, and FTO influence how efficiently your GLP-1 pathways function and regulate appetite and energy expenditure. Two people on identical semaglutide doses may experience different rates of weight loss because their genetic profiles create different baseline sensitivities to the medication's effects.
Lifestyle factors—including dietary quality, physical activity, sleep patterns, and stress management—directly impact semaglutide results. Patients who combine medication with consistent walking, strength training, or other exercise typically see better outcomes than those relying on medication alone. Adherence to your prescribed dose and regular follow-up appointments also influence success; skipping doses or inconsistent use diminishes the medication's effectiveness.
Age, baseline metabolism, prior weight loss attempts, and presence of weight-related conditions (such as type 2 diabetes) also shape your individual trajectory. Older adults sometimes experience slightly slower weight loss, while those with metabolic disorders may benefit from more aggressive dosing strategies under medical supervision.
Realistic Weight Loss Goals and Timeline
A reasonable first-month expectation is 1–2 pounds of weight loss as your body begins responding to semaglutide's appetite-suppressing signal. By month three, many patients report 5–10 pounds of cumulative weight loss, though this varies. By the end of six months of consistent therapy at therapeutic doses, 10–20 pounds of weight loss is common, though some patients lose more and others less.
Setting a target of 10–15 percent of your body weight as a first-phase goal (typically achievable within 6–12 months) is realistic and clinically meaningful for reducing risk factors such as high blood pressure, high cholesterol, and blood sugar elevation. Once you reach a stable weight loss plateau, many patients maintain their results through continued medication use, regular physical activity, and sustained dietary improvements.
Weight loss is not always linear; some weeks you may see progress, while others show no change or slight fluctuations. These plateaus are normal and do not indicate treatment failure. Continuing therapy and maintaining healthy habits usually leads to gradual progress over months rather than expecting dramatic results weekly.
How PlexusDx Personalizes Your Semaglutide Strategy
PlexusDx offers compounded semaglutide injection starting at $149 per month, available to all 50 states without insurance requirements. Your medication is prepared by licensed 503A compounding pharmacies using pharmaceutical-grade ingredients, ensuring safety and purity. PlexusDx also provides access to the Precision Peptide Genetic Test ($99 add-on after your first month), which analyzes your GLP-1 pathway genetics to reveal how your body's natural appetite and energy systems are wired.
The Precision Peptide Genetic Test examines key variants in GLP1R, GIPR, FTO, and MC4R genes, mapping your results across 14 metabolic pathways and 49 peptide-related genes. This insight helps your PlexusDx provider understand whether you may need standard dosing, higher doses for stronger response, or a different compound entirely—such as tirzepatide (a dual GLP-1 and GIP receptor agonist) if your GIPR genetics suggest enhanced benefit. Personalized dosing recommendations based on your genetic profile increase the likelihood of meaningful weight loss while minimizing unnecessary escalation.
PlexusDx medications are HSA/FSA eligible, and your dose may increase as you progress toward your goal—but your price remains flat. This transparent pricing model eliminates surprise costs at higher doses, allowing you to focus on results rather than worrying about escalating expenses.
Maintaining Weight Loss After Semaglutide Success
Research shows that weight regain occurs in many patients who stop semaglutide therapy, as appetite hormones gradually return to baseline levels. Continuing semaglutide at a maintenance dose—often lower than the dose used to achieve initial weight loss—helps preserve your results long-term. PlexusDx supports ongoing therapy at a consistent flat monthly rate, making sustained treatment financially predictable.
Pairing semaglutide therapy with permanent lifestyle changes—such as adopting a higher-protein diet, building a regular exercise routine, and establishing sleep and stress-management practices—creates the strongest foundation for lasting weight loss. Genetic insights from the Precision Peptide Genetic Test can also guide your nutritional approach; for example, if your FTO variant suggests increased hunger signaling, a higher-protein breakfast may help you feel fuller longer and avoid afternoon cravings.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
How much weight can I realistically lose on semaglutide in the first three months?
Most patients lose 5–10 pounds in the first three months as the medication reaches therapeutic doses. Individual results depend on your starting weight, genetics, diet quality, and exercise habits. PlexusDx tracks your progress and adjusts your treatment plan to optimize outcomes over time.
Does semaglutide work better for some people than others, and why?
Yes—genetic variations in your GLP-1 and GIP receptor genes significantly influence how effectively semaglutide suppresses your appetite and supports weight loss. PlexusDx's Precision Peptide Genetic Test ($99 after first month) identifies these variants, helping your provider choose the ideal dose or compound for your biology.
What is the cost of semaglutide therapy with PlexusDx?
PlexusDx compounded semaglutide injection starts at $149 per month across all commitment tiers, with no insurance required, no membership fees, and HSA/FSA eligibility. Your dose may increase as you progress—but your price stays flat.
Is PlexusDx compounded semaglutide safe and as effective as brand-name Wegovy?
Yes. PlexusDx semaglutide is prepared by licensed 503A compounding pharmacies using the same pharmaceutical-grade active ingredient as brand medications. Compounding allows for flexible dosing and personalized protocols that may enhance your individual outcomes. Your provider monitors your safety and progress throughout treatment.
How does the Precision Peptide Genetic Test help with weight loss?
The test analyzes 14 metabolic pathways and 49 peptide genes, including GLP1R, GIPR, FTO, and MC4R variants that influence hunger, fullness signaling, and energy use. These insights guide dose selection and may indicate whether semaglutide, tirzepatide, or a dual compound is best suited to your genetic profile—increasing your chances of meaningful, sustainable weight loss.
Related Reading
Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Ozempic Affects Appetite: Understanding Its Impact on Your Eating Habits
Will Insurance Companies Cover Ozempic for Weight Loss?